EWS and RE1-Silencing Transcription Factor Inhibit Neuronal Phenotype Development and Oncogenic Transformation in Ewing Sarcoma

Genes and Cancer

Volumn 4, Issue 5-6, 2013, Pages 213-223

  Sankar, Savita ^a   Gomez, Nicholas C ^b   Bell, Russell ^c   Patel, Mukund ^b,d   Davis, Ian J ^b,d   Lessnick, Stephen L ^a,c   Luo, Wen ^a,c,e  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Ewing sarcoma; EWS; neuronal phenotype; oncogenic transformation; REST

Indexed keywords

NEURON RESTRICTIVE SILENCER ELEMENT; NEURON RESTRICTIVE SILENCER FACTOR; ONCOPROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CELL FUNCTION; CONTROLLED STUDY; DOWN REGULATION; EWING SARCOMA; EWS GENE; GENE CLUSTER; GENE CONTROL; GENE FUNCTION; GENE SEQUENCE; GENE SILENCING; GENE TRANSLOCATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MALIGNANT TRANSFORMATION; NUCLEOTIDE SEQUENCE; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

EID: 84887424861     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601913489569     Document Type: Article

References (59)

1. Smith R,Owen LA,Trem DJ, et al.Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma.Cancer Cell. 2006;9:405-16.
2. Kinsey M,Smith R,Lessnick SL.NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma.Mol Cancer Res. 2006;4:851-9.
3. Luo W,Gangwal K,Sankar S,Boucher KM,Thomas D,Lessnick SL.GSTM4 is a microsatellite-containing EWS/FLI target involved in Ewing's sarcoma oncogenesis and therapeutic resistance.Oncogene. 2009;28:4126-32.
4. Kovar H,Jug G,Hattinger C, et al.The EWS protein is dispensable for Ewing tumor growth.Cancer Res. 2001;61:5992-7.
5. Law WJ,Cann KL,Hicks GG.TLS, EWS and TAF15: a model for transcriptional integration of gene expression.Brief Funct Genomic Proteomic. 2006;5:8-14.
6. Paronetto MP,Minana B,Valcarcel J.The Ewing sarcoma protein regulates DNA damage-induced alternative splicing.Mol Cell. 2011;43:353-68.
7. Dutertre M,Sanchez G,De Cian MC, et al.Cotranscriptional exon skipping in the genotoxic stress response.Nat Struct Mol Biol. 2010;17:1358-66.
8. Wang X,Arai S,Song X, et al.Induced ncRNAs allosterically modify RNA-binding proteins in cis to inhibit transcription.Nature. 2008;454:126-30.
9. Kato M,Han TW,Xie S, et al.Cell-free formation of RNA granules: low complexity sequence domains form dynamic fibers within hydrogels.Cell. 2012;149:753-67.
10. Blechingberg J,Luo Y,Bolund L,Damgaard CK,Nielsen AL.Gene expression responses to FUS, EWS, and TAF15 reduction and stress granule sequestration analyses identifies FET-protein non-redundant functions.PLoS One. 2012;7:e46251.
11. Spahn L,Siligan C,Bachmaier R,Schmid JA,Aryee DN,Kovar H.Homotypic and heterotypic interactions of EWS, FLI1 and their oncogenic fusion protein.Oncogene. 2003;22:6819-29.
12. Embree LJ,Azuma M,Hickstein DD.Ewing sarcoma fusion protein EWSR1/FLI1 interacts with EWSR1 leading to mitotic defects in Zebrafish embryos and human cell lines.Cancer Res. 2009;69:4363-71.
13. Yang L,Chansky HA,Hickstein DD.EWS.Fli-1 fusion protein interacts with hyperphosphorylated RNA polymerase II and interferes with serine-arginine protein-mediated RNA splicing.J Biol Chem. 2000;275:37612-8.
14. Lipinski M,Hirsch MR,Deagostini-Bazin H,Yamada O,Tursz J,Goridis C.Characterization of neural cell adhesion molecules (NCAM) expressed by Ewing and neuroblastoma cell lines.Int J Cancer. 1987;40:81-6.
15. Cavazzana AO,Miser JS,Jefferson J,Triche TJ.Experimental evidence for a neural origin of Ewing's sarcoma of bone.Am J Pathol. 1987;127:507-18.
16. Teitell MA,Thompson AD,Sorensen PH,Shimada H,Triche TJ,Denny CT.EWS/ETS fusion genes induce epithelial and neuroectodermal differentiation in NIH 3T3 fibroblasts.Lab Invest. 1999;79:1535-43.
17. Hu-Lieskovan S,Zhang J,Wu L,Shimada H,Schofield DE,Triche TJ.EWS-FLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing's family of tumors.Cancer Res. 2005;65:4633-44.
18. Turc-Carel C,Philip I,Berger MP,Philip T,Lenoir GM.Chromosome study of Ewing's sarcoma (ES) cell lines: consistency of a reciprocal translocation t(11;22)(q24;q12).Cancer Genet Cytogenet. 1984;12:1-19.
19. Aurias A,Rimbaut C,Buffe D,Zucker JM,Mazabraud A.Translocation involving chromosome 22 in Ewing's sarcoma: a cytogenetic study of four fresh tumors.Cancer Genet Cytogenet. 1984;12:21-5.
20. Whang-Peng J,Triche TJ,Knutsen T,Miser J,Douglass EC,Israel MA.Chromosome translocation in peripheral neuroepithelioma.N Engl J Med. 1984;311:584-5.
21. Jones FS,Meech R.Knockout of REST/NRSF shows that the protein is a potent repressor of neuronally expressed genes in non-neural tissues.BioEssays. 1999;21:372-6.
22. Majumder S.REST in good times and bad: roles in tumor suppressor and oncogenic activities.Cell Cycle. 2006;5:1929-35.
23. Qureshi IA,Mehler MF.Regulation of non-coding RNA networks in the nervous system: what's the REST of the story?.Neurosci Lett. 2009;466:73-80.
24. Westbrook TF,Martin ES,Schlabach MR, et al.A genetic screen for candidate tumor suppressors identifies REST.Cell. 2005;121:837-48.
25. Coulson JM,Edgson JL,Woll PJ,Quinn JP.A splice variant of the neuron-restrictive silencer factor repressor is expressed in small cell lung cancer: a potential role in derepression of neuroendocrine genes and a useful clinical marker.Cancer Res. 2000;60:1840-4.
26. Gurrola-Diaz C,Lacroix J,Dihlmann S,Becker CM,von Knebel Doeberitz M.Reduced expression of the neuron restrictive silencer factor permits transcription of glycine receptor alpha1 subunit in small-cell lung cancer cells.Oncogene. 2003;22:5636-45.
27. Fuller GN,Su X,Price RE, et al.Many human medulloblastoma tumors overexpress repressor element-1 silencing transcription (REST)/neuron-restrictive silencer factor, which can be functionally countered by REST-VP16.Mol Cancer Ther. 2005;4:343-9.
28. Wagoner MP,Gunsalus KT,Schoenike B,Richardson AL,Friedl A,Roopra A.The transcription factor REST is lost in aggressive breast cancer.PLoS Genet. 2010;6:e1000979.
29. Irizarry RA,Wang C,Zhou Y,Speed TP.Gene set enrichment analysis made simple.Stat Methods Med Res. 2009;18:565-75.
30. Khan MO,Ather MH.Chromogranin A: serum marker for prostate cancer.J Pak Med Assoc. 2011;61:108-11.
31. Berton F,Iborra C,Boudier JA,Seagar MJ,Marqueze B.Developmental regulation of synaptotagmin I, II, III, and IV mRNAs in the rat CNS.J Neurosci. 1997;17:1206-16.
32. Hahm S,Mizuno TM,Wu TJ, et al.Targeted deletion of the Vgf gene indicates that the encoded secretory peptide precursor plays a novel role in the regulation of energy balance.Neuron. 1999;23:537-48.
33. Alder J,Thakker-Varia S,Bangasser DA, et al.Brain-derived neurotrophic factor-induced gene expression reveals novel actions of VGF in hippocampal synaptic plasticity.J Neurosci. 2003;23:10800-8.
34. Li F,Tian X,Zhou Y, et al.Dysregulated expression of secretogranin III is involved in neurotoxin-induced dopaminergic neuron apoptosis.J Neurosci Res. 2012;90:2237-46.
35. Perletti L,Talarico D,Trecca D, et al.Identification of a novel gene, PSD, adjacent to NFKB2/lyt-10, which contains Sec7 and pleckstrin-homology domains.Genomics. 1997;46:251-9.
36. Wu JT,Erickson AJ,Tsao KC,Wu TL,Sun CF.Elevated serum chromogranin A is detectable in patients with carcinomas at advanced disease stages.Ann Clin Lab Sci. 2000;30:175-8.
37. Moss AC,Jacobson GM,Walker LE,Blake NW,Marshall E,Coulson JM.SCG3 transcript in peripheral blood is a prognostic biomarker for REST-deficient small cell lung cancer.Clin Cancer Res. 2009;15:274-83.
38. Matsumoto T,Kawashima Y,Nagashio R, et al.A new possible lung cancer marker: VGF detection from the conditioned medium of pulmonary large cell neuroendocrine carcinoma-derived cells using secretome analysis.Int J Biol Markers. 2009;24:282-5.
39. Schoenherr CJ,Paquette AJ,Anderson DJ.Identification of potential target genes for the neuron-restrictive silencer factor.Proc Natl Acad Sci U S A. 1996;93:9881-6.
40. Otto SJ,McCorkle SR,Hover J, et al.A new binding motif for the transcriptional repressor REST uncovers large gene networks devoted to neuronal functions.J Neurosci. 2007;27:6729-39.
41. Jørgensen HF,Terry A,Beretta C, et al.REST selectively represses a subset of RE1-containing neuronal genes in mouse embryonic stem cells.Development. 2009;136:715-21.
42. Bertolotti A,Melot T,Acker J,Vigneron M,Delattre O,Tora L.EWS, but not EWS-FLI-1, is associated with both TFIID and RNA polymerase II: interactions between two members of the TET family, EWS and hTAFII68, and subunits of TFIID and RNA polymerase II complexes.Mol Cell Biol. 1998;18:1489-97.
43. Thomas GR,Latchman DS.The pro-oncoprotein EWS (Ewing's sarcoma protein) interacts with the Brn-3a POU transcription factor and inhibits its ability to activate transcription.Cancer Biol Ther. 2002;1:428-32.
44. Gao Z,Ure K,Ding P, et al.The master negative regulator REST/NRSF controls adult neurogenesis by restraining the neurogenic program in quiescent stem cells.J Neurosci1999. 2011;31:9772-86.
45. Patel M,Simon JM,Iglesia MD, et al.Tumor-specific retargeting of an oncogenic transcription factor chimera results in dysregulation of chromatin and transcription.Genome Res. 2012;22:259-70.
46. Rashid NU,Giresi PG,Ibrahim JG,Sun W,Lieb JD.ZINBA integrates local covariates with DNA-seq data to identify broad and narrow regions of enrichment, even within amplified genomic regions.Genome Biol. 2011;12:R67.
47. Rocchi A,Manara MC,Sciandra M, et al.CD99 inhibits neural differentiation of human Ewing sarcoma cells and thereby contributes to oncogenesis.J Clin Invest. 2010;120:668-80.
48. Sanchez G,Bittencourt D,Laud K, et al.Alteration of cyclin D1 transcript elongation by a mutated transcription factor up-regulates the oncogenic D1b splice isoform in cancer.Proc Natl Acad Sci U S A. 2008;105:6004-9.
49. Sankar S,Bell R,Stephens B, et al.Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma.Oncogene. 2012;:.
50. Ordonez NG.Desmoplastic small round cell tumor, I: a histopathologic study of 39 cases with emphasis on unusual histological patterns.Am J Surg Pathol. 1998;22:1303-13.
51. Goh YW,Spagnolo DV,Platten M, et al.Extraskeletal myxoid chondrosarcoma: a light microscopic, immunohistochemical, ultrastructural and immuno-ultrastructural study indicating neuroendocrine differentiation.Histopathology. 2001;39:514-24.
52. Tsai MC,Manor O,Wan Y, et al.Long noncoding RNA as modular scaffold of histone modification complexes.Science. 2010;329:689-93.
53. Huang L,Nakai Y,Kuwahara I,Matsumoto K.PRAS40 is a functionally critical target for EWS repression in Ewing sarcoma.Cancer Res. 2012;72:1260-9.
54. Tawadros T,Martin D,Abderrahmani A,Leisinger HJ,Waeber G,Haefliger JA.IB1/JIP-1 controls JNK activation and increased during prostatic LNCaP cells neuroendocrine differentiation.Cell Signal. 2005;17:929-39.
55. Yeo M,Lee SK,Lee B,Ruiz EC,Pfaff SL,Gill GN.Small CTD phosphatases function in silencing neuronal gene expression.Science. 2005;307:596-600.
56. Lessnick SL,Dacwag CS,Golub TR.The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts.Cancer Cell. 2002;1:393-401.
57. Lessnick SL,Braun BS,Denny CT,May WA.Multiple domains mediate transformation by the Ewing's sarcoma EWS/FLI-1 fusion gene.Oncogene. 1995;10:423-31.
58. Subramanian A,Tamayo P,Mootha VK, et al.Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.Proc Natl Acad Sci U S A. 2005;102:15545-50.
59. Daily K,Patel VR,Rigor P,Xie X,Baldi P.MotifMap: integrative genome-wide maps of regulatory motif sites for model species.BMC Bioinformatics. 2011;12:495.